Security Snapshot

Arcellx, Inc. - Common Stock, par value $0.001 per share (ACLX) Institutional Ownership

CUSIP: 03940C100

13F Institutional Holders and Ownership History from Q1 2022 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

238

Shares (Excl. Options)

56,563,116

Price

$114.82

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
-11,314,057
Value change
-$794,507,222
Number of holders
238
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
100
SEC-reported price per share
$115.07
Insider filing price
$115.07
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • ACLX - Arcellx, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 03940C100.
  • 238 institutions reported positions in Q1 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 238 to 0 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $6,464,989,000 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 238 institutions filings for Q1 2026.

Open SEC evidence

Security key

03940C100

Latest holder period

Q1 2026

13F holders

238

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
ACLX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Paradigm Biocapital Advisors LP 9.9% $379,330,540 5,724,016 Paradigm BioCapital Advisors LP 31 Dec 2025
BlackRock, Inc. 6.4% $228,246,406 3,527,220 BlackRock, Inc. 31 Mar 2025
T. Rowe Price Investment Management, Inc. 4.5% -77% $185,450,898 -$552,511,601 2,653,848 -75% T. Rowe Price Investment Management, Inc. 28 Feb 2026
PERCEPTIVE ADVISORS LLC 4.5% -16% $162,432,900 -$29,397,733 2,478,000 -15% Perceptive Advisors LLC 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P. 2.2% $83,974,428 1,267,156 RA Capital Management, L.P. 31 Dec 2025
FMR LLC 0.5% -95% $21,601,128 -$227,432,217 309,117 -91% FMR LLC 27 Feb 2026
GILEAD SCIENCES, INC. 100% +738% $11,482 -$771,671,118 100 -100% GILEAD SCIENCES, INC. 28 Apr 2026

As of 31 Mar 2026, 238 institutional investors reported holding 56,563,116 shares of Arcellx, Inc. - Common Stock, par value $0.001 per share (ACLX). This represents 56563116% of the company’s total 100 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
47406512%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 6720803% 6,720,803 0% 36% $771,682,600
Paradigm Biocapital Advisors LP 5774016% 5,774,016 +0.87% 14% $662,972,517
BlackRock, Inc. 3945238% 3,945,238 +11% 0.01% $452,992,229
NEA Management Company, LLC 3045262% 3,045,262 0% 20% $349,656,983
Pentwater Capital Management LP 2870000% 2,870,000 2.3% $329,533,400
VANGUARD CAPITAL MANAGEMENT LLC 2425218% 2,425,218 0% 0.01% $278,463,531
VANGUARD PORTFOLIO MANAGEMENT LLC 2424818% 2,424,818 0% 0.01% $278,417,603
SR One Capital Management, LP 2346630% 2,346,630 0% 29% $269,440,057
FIL Ltd 2339192% 2,339,192 0.21% $268,586,025
HBK INVESTMENTS L P 2278517% 2,278,517 3.3% $261,619,322
T. Rowe Price Investment Management, Inc. 2255878% 2,255,878 -79% 0.18% $259,020,000
STATE STREET CORP 1675895% 1,675,895 -16% 0.01% $192,426,264
GLAZER CAPITAL, LLC 1507128% 1,507,128 3.7% $173,048,000
GOLDMAN SACHS GROUP INC 1312155% 1,312,155 +96% 0.02% $150,661,637
GEODE CAPITAL MANAGEMENT, LLC 1028666% 1,028,666 +7.4% 0.01% $118,135,702
MORGAN STANLEY 925813% 925,813 +79% 0.01% $106,301,939
JPMORGAN CHASE & CO 593573% 593,573 -59% 0% $68,124,374
Davidson Kempner Capital Management LP 559644% 559,644 1.4% $64,258,324
ALLIANCEBERNSTEIN L.P. 544227% 544,227 +1234% 0.01% $35,483,600
TIG Advisors, LLC 541378% 541,378 3% $62,161,022
MILLENNIUM MANAGEMENT LLC 502846% 502,846 +5601% 0.04% $57,736,778
Balyasny Asset Management L.P. 479763% 479,763 0.11% $55,086,388
TUDOR INVESTMENT CORP ET AL 462588% 462,588 +905% 0.29% $53,114,354
BANK OF AMERICA CORP /DE/ 452333% 452,333 +5.7% 0% $51,936,876
Magnetar Financial LLC 394931% 394,931 0.46% $45,345,977

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
18
Latest
Q1 2026
Rows shown
1-18 of 18
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 0 $0 -$7,034,328 $115.07 0
2026 Q1 56,563,116 $6,464,989,000 -$794,507,222 $114.82 238
2025 Q4 66,618,337 $4,343,544,589 +$191,098,400 $65.20 218
2025 Q3 63,039,877 $5,175,204,679 +$190,810,895 $82.10 207
2025 Q2 60,837,024 $4,006,426,303 -$46,745,437 $65.85 200
2025 Q1 61,569,105 $4,042,657,536 +$146,759,811 $65.60 195
2024 Q4 59,173,488 $4,537,933,690 +$127,885,655 $76.69 208
2024 Q3 49,489,073 $4,134,912,072 -$113,389,722 $83.51 185
2024 Q2 50,216,931 $2,771,120,513 +$171,282,810 $55.19 164
2024 Q1 47,012,321 $3,269,162,577 +$35,796,177 $69.55 180
2023 Q4 46,737,558 $2,593,995,956 -$29,980,183 $55.50 154
2023 Q3 47,577,643 $1,707,089,455 -$7,341,800 $35.88 132
2023 Q2 48,066,751 $1,519,832,876 +$79,444,997 $31.62 134
2023 Q1 45,593,955 $1,403,613,948 +$114,227,065 $30.81 115
2022 Q4 41,987,329 $1,300,761,660 +$53,764,127 $30.98 123
2022 Q3 41,706,487 $782,853,521 +$127,574,774 $18.77 74
2022 Q2 34,934,000 $621,506,000 +$145,615,758 $18.08 67
2022 Q1 26,872,990 $357,855,000 +$357,824,000 $14.02 48
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .